These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Manuscript.pdf (2.42 MB)

Gibberellin JRA-003: A Selective Inhibitor of Nuclear Translocation of IKKalpha

submitted on 16.12.2019, 23:11 and posted on 20.12.2019, 09:54 by James Annand, Andrew Henderson, Kyle Cole, Aaron Maurais, Jorge Becerra, Yejun Liu, Eranthie Weerapana, Angela Koehler, Anna Mapp, Corinna Schindler
The small molecule gibberellin JRA-003 (1) was identified as an inhibitor of the NF-kB (nuclear kappa-light-chain enhancer of activated B cells) pathway. Here we find that JRA-003 binds to and significantly inhibits the nuclear translocation of pathway-activating kinases IKKalpha (IkB kinase alpha) and IKKbeta (IkB kinase beta). Analogs were synthesized and NF-kB-inhibiting gibberellins were found to be cytotoxic in cancer-derived cell lines (HS 578T, HCC 1599, RC-K8, Sud-HL4, CA 46, and NCIH 4466). Not only was JRA-003 (1) identified as the most potent synthetic gibberellin against cancer-derived cell lines, it displayed no cytotoxicity in cells derived from non-cancerous sources (HEK 293T, HS 578BST, HS 888Lu, HS 895Sk, HUVEC). This selectivity suggests a promising approach for the development of new therapeutics.


David and Lucile Packard Foundation

Alfred P. Sloan Foundation

Camille and Henry Dreyfus Foundation

Koch Institute Cancer Center Support Core Grant (P30-CA14051)


Email Address of Submitting Author


University of Michigan


United States

ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest